Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma
暂无分享,去创建一个
Yuan Ji | Paolo Anderlini | A. Younes | L. Kwak | U. Popat | Yuan Ji | L. Fayad | Anas Younes | Uday Popat | M. Fanale | B. Pro | Barbara Pro | Felipe Samaniego | Luis Fayad | P. Anderlini | F. Samaniego | Michelle Fanale | Mary Joy Liboon | Cesar Nunez | Sandra Horowitz | Larry W. Kwak | C. Nunez | S. Horowitz | Mary Joy Liboon
[1] C. Gisselbrecht,et al. The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation , 2007, Cancer.
[2] Yuan Ji,et al. Dose-finding in phase I clinical trials based on toxicity probability intervals , 2007, Clinical trials.
[3] E. Vellenga,et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. , 2007, Blood.
[4] O. Sezer,et al. Bortezomib Is Not Active in Patients with Relapsed Hodgkin’s Lymphoma: Results of a Prematurely Closed Phase II Study. , 2006 .
[5] B. Cheson,et al. A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Lister,et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Younes,et al. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. , 2006, Blood.
[8] B. Aggarwal,et al. Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors , 2004, Clinical Cancer Research.
[9] A. Zelenetz,et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.